Recent Quotes (30 days)

You have no recent quotes
chg | %

Tekmira Pharmaceuticals Corp  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
22.97
Mar 3 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 9.55 - 34.66
Open     -
Vol / Avg. 0.00/31,124.00
Mkt cap 502.11M
P/E     -
Div/yield     -
EPS -2.15
Shares 22.31M
Beta -0.58
Inst. own     -
Aug 11, 2015
Q2 2015 Tekmira Pharmaceuticals Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
Tekmira Pharmaceuticals Corp at JMP Securities Life Sciences Conference - 4:00PM EDT - Add to calendar
Jun 2, 2015
Tekmira Pharmaceuticals Corp at Jefferies Global Healthcare Conference - 3:30PM EDT - Add to calendar
May 7, 2015
Tekmira Pharmaceuticals Corp at Deutsche Bank Health Care Conference
May 6, 2015
Q1 2015 Tekmira Pharmaceuticals Corp Earnings Call - Webcast
May 6, 2015
Q1 2015 Tekmira Pharmaceuticals Corp Earnings Release
Mar 12, 2015
Q4 2014 Tekmira Pharmaceuticals Corp Earnings Call - Webcast
Mar 12, 2015
Q4 2014 Tekmira Pharmaceuticals Corp Earnings Release
Mar 11, 2015
Tekmira Pharmaceuticals Corp at Barclays Healthcare Conference - Webcast
Mar 3, 2015
Tekmira Pharmaceuticals Corp Extraordinary Shareholders Meeting
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -

Address

100-8900 Glenlyon Pky
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

Description

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Its product candidates include TKM-HBV, TKM-PLK1, TKM-Ebola and TKM-Marburg. TKM-HBV is an RNAi therapeutic for the treatment of Hepatitis B infection. The Company’s lead oncology product candidate, TKM -PLK1 is an oncology product platform that targets polo-like kinase 1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target. TKM-ALDH2 is an application of RNAi for alcohol use disorder with a target patient population who have moderate to severe alcohol use disorder. TKM-Ebola is an anti-Ebola viral therapeutic being developed under a contract with the United States Department of Defense Joint Project Manager Medical Countermeasure Systems. TKM-Marburg is used to treat hemorrhagic fever viral infections.